Conventional therapy ( DrugBank: - )


2 diseases
IDDisease name (Link within this page)Number of trials
67Polycystic kidney disease2
222Primary nephrotic syndrome3

67. Polycystic kidney disease


Clinical trials : 221 Drugs : 212 - (DrugBank : 55) / Drug target genes : 40 - Drug target pathways : 151
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01223755
(ClinicalTrials.gov)
September 201012/10/2010Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal InsufficiencyEFFECTS OF SIROLIMUS ON DISEASE PROGRESSION IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE AND SEVERE RENAL INSUFFICIENCYAutosomal Dominant Polycystic Kidney Disease (ADPKD)Drug: Sirolimus;Drug: conventional therapyMario Negri Institute for Pharmacological ResearchNULLTerminated18 Years80 YearsBoth41Phase 2/Phase 3Italy
2NCT00491517
(ClinicalTrials.gov)
March 200725/6/2007Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and SafetySirolimus Treatment in Patients With ADPKDPolycystic KidneyDrug: Sirolimus;Drug: conventional therapyMario Negri Institute for Pharmacological ResearchNULLCompleted18 Years80 YearsBoth22Phase 2Italy

222. Primary nephrotic syndrome


Clinical trials : 310 Drugs : 295 - (DrugBank : 117) / Drug target genes : 63 - Drug target pathways : 194
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR2200057174
2022-02-202022-03-02Efficacy and safety of glutamine combined with Clostridium butyricum in the treatment of hormone-dependent minor lesion nephropathyEfficacy and safety of glutamine combined with Clostridium butyricum in the treatment of hormone-dependent minor lesion nephropathy Primary nephrotic syndromeControl group:Conventional therapy (steroid+rituximab);Intervention group:Conventional treatment + glutamine + clostridium butyric acid;Shanghai Children's HospitalNULLPending118BothControl group:49;Intervention group:49;China
2ChiCTR2100050967
2021-09-302021-09-08A controlled clinical trial of the efficacy and safety of sacubitril/valsartan in reducing urinary protein in patients with low-risk membranous nephropathyA controlled clinical trial of the efficacy and safety of sacubitril/valsartan in reducing urinary protein in patients with low-risk membranous nephropathy membranous nephropathyExperimental group:Conventional therapy+sacubitril/valsartan 100mg bid;Control group:Conventional therapy+valsartan 160mg qd;China-Japan Friendship HospitalNULLRecruiting3075BothExperimental group:50;Control group:50;Phase 4China
3NCT02966717
(ClinicalTrials.gov)
August 201630/10/2016Rituximab Combined With MSCs in the Treatment of PNS (3-4 Stage of CKD)The Clinical Study of Rituximab Combined With Mesenchymal Stem Cells in the Treatment of Primary Nephrotic Syndrome (3-4 Stage of Chronic Kidney Disease)Renal Insufficiency, Chronic;Nephrotic SyndromeDrug: Rituximab;Drug: conventional therapy;Drug: Mesenchymal stem cellsZhujiang HospitalNULLActive, not recruiting18 Years65 YearsBoth116Phase 2China